XFOR - X4 Pharmaceuticals Inc
4.15
0.390 9.398%
Share volume: 590,387
Last Updated: 03-09-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.00%
PREVIOUS CLOSE
CHG
CHG%
$3.76
0.39
0.10%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-07-2024 | 08-08-2024 | 11-13-2024 | 03-25-2025 | 05-01-2025 | 08-08-2025 | 11-05-2025 | |
| Assets | ||||||||
| Total Assets | 112.182 M | 210.611 M | 178.165 M | 146.447 M | 130.013 M | 105.168 M | 163.555 M | |
| Current Assets | 87.333 M | 175.416 M | 142.972 M | 112.175 M | 95.697 M | 72.942 M | 132.805 M | |
| Inventories | 0.000 | 831.000 K | 2.445 M | 2.817 M | 3.089 M | 3.170 M | 4.080 M | |
| Other Current Assets | 702.000 K | 854.000 K | 1.073 M | 640.000 K | 665.000 K | 720.000 K | 715.000 K | |
| Short Term Investments | 20.376 M | 21.536 M | 37.565 M | 46.361 M | 46.694 M | 23.731 M | 52.562 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 60.493 M | 147.218 M | 97.412 M | 55.699 M | 40.257 M | 39.220 M | 69.632 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 742.000 K | 808.000 K | 820.000 K | 776.000 K | 487.000 K | 254.000 K | 218.000 K | |
| Other Assets | 24.107 M | 34.387 M | 34.373 M | 33.496 M | 33.829 M | 31.972 M | 30.532 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 112.182 M | 210.611 M | 178.165 M | 146.447 M | 130.013 M | 105.168 M | 163.555 M | |
| Total liabilities | 111.146 M | 116.160 M | 118.544 M | 124.298 M | 107.069 M | 101.197 M | 101.936 M | |
| Total current liabilities | 23.541 M | 28.902 M | 29.258 M | 32.877 M | 25.884 M | 22.896 M | 23.506 M | |
| Accounts Payable | 8.935 M | 7.986 M | 8.577 M | 8.621 M | 11.115 M | 7.709 M | 5.053 M | |
| Other liabilities | 32.781 M | 12.228 M | 14.062 M | 15.996 M | 4.601 M | 1.633 M | 1.579 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 54.824 M | 75.030 M | 75.224 M | 75.425 M | 75.629 M | 75.841 M | 76.062 M | |
| Other liabilities | 32.781 M | 12.228 M | 14.062 M | 15.996 M | 4.601 M | 1.633 M | 1.579 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.036 M | 94.451 M | 59.621 M | 22.149 M | 22.944 M | 3.971 M | 61.619 M | |
| Common stock | 530.862 M | 533.448 M | 535.269 M | 537.626 M | 538.145 M | 544.923 M | 632.366 M | |
| Retained earnings | -529.671 M | -438.838 M | -475.534 M | -515.355 M | -515.073 M | -540.814 M | -570.629 M |